FCER2 and B-cell chronic lymphocytic leukemia: The evolution of CLL treatment is further underscored by the historical progression from the approval of Rituximab and Alemtuzumab [9] to the initiation of clinical trials for novel monoclonal antibodies targeting CD20 and CD23, as well as the advent of innovative immunotherapeutic strategies, indicating a profound transformation in the field [10].